These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 16580110

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An open study of risperidone liquid in the acute phase of schizophrenia.
    Yoshimura R, Nakamura J, Shinkai K, Goto M, Yamada Y, Kaji K, Kakihara S, Ueda N, Kohara K, Ninomiya H, Egami H, Maeda H.
    Hum Psychopharmacol; 2005 Jun; 20(4):243-8. PubMed ID: 15830401
    [Abstract] [Full Text] [Related]

  • 4. Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study.
    Vieta E, Goikolea JM, Corbella B, Benabarre A, Reinares M, Martínez G, Fernández A, Colom F, Martínez-Arán A, Torrent C, Group for the Study of Risperidone in Affective Disorders (GSRAD).
    J Clin Psychiatry; 2001 Oct; 62(10):818-25. PubMed ID: 11816872
    [Abstract] [Full Text] [Related]

  • 5. Valproic acid improves psychotic agitation without influencing plasma risperidone levels in schizophrenic patients.
    Yoshimura R, Shinkai K, Ueda N, Nakamura J.
    Pharmacopsychiatry; 2007 Jan; 40(1):9-13. PubMed ID: 17327954
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Risperidone in the early treatment of first-episode psychosis: a two-year follow-up study].
    Gutiérrez Fraile M, Segarra Echevarría R, González-Pinto Arrillaga A, Martínez Junquera G.
    Actas Esp Psiquiatr; 2002 Jan; 30(3):142-52. PubMed ID: 12106515
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors.
    Yukimasa T, Yoshimura R, Tamagawa A, Uozumi T, Shinkai K, Ueda N, Tsuji S, Nakamura J.
    Pharmacopsychiatry; 2006 Mar; 39(2):52-9. PubMed ID: 16555165
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of imipramine in psychotic versus nonpsychotic depression.
    Birkenhager TK, van den Broek WW, Mulder PG, Moleman P, Bruijn JA.
    J Clin Psychopharmacol; 2008 Apr; 28(2):166-70. PubMed ID: 18344726
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression.
    Politis AM, Papadimitriou GN, Theleritis CG, Psarros C, Soldatos CR.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul 01; 32(5):1227-30. PubMed ID: 18442877
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
    Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L.
    Eur Neuropsychopharmacol; 2005 Jan 01; 15(1):69-74. PubMed ID: 15572275
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
    Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA.
    J Affect Disord; 2004 Dec 01; 83(2-3):263-75. PubMed ID: 15555724
    [Abstract] [Full Text] [Related]

  • 18. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
    Sheehan DV, McElroy SL, Harnett-Sheehan K, Keck PE, Janavs J, Rogers J, Gonzalez R, Shivakumar G, Suppes T.
    J Affect Disord; 2009 Jun 01; 115(3):376-85. PubMed ID: 19042026
    [Abstract] [Full Text] [Related]

  • 19. Long-acting risperidone in stable patients with schizoaffective disorder.
    Mohl A, Westlye K, Opjordsmoen S, Lex A, Schreiner A, Benoit M, Bräunig P, Medori R.
    J Psychopharmacol; 2005 Sep 01; 19(5 Suppl):22-31. PubMed ID: 16144783
    [Abstract] [Full Text] [Related]

  • 20. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
    Kakihara S, Yoshimura R, Shinkai K, Matsumoto C, Goto M, Kaji K, Yamada Y, Ueda N, Ohmori O, Nakamura J.
    Int Clin Psychopharmacol; 2005 Mar 01; 20(2):71-8. PubMed ID: 15729081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.